Literature DB >> 1885420

Comparative activities of amoxycillin, amoxycillin/clavulanic acid and tetracycline against Chlamydia trachomatis in cell culture and in an experimental mouse pneumonitis.

A S Beale1, E Faulds, S E Hurn, J Tyler, B Slocombe.   

Abstract

The activity of amoxycillin, amoxycillin/clavulanic acid and two tetracycline antibiotics was investigated against three strains of Chlamydia trachomatis in vitro. McCoy cells were infected and single doses of antibiotic administered 24 h after infection. The percentage of infected cells was calculated at intervals up to 72 h after infection. Amoxycillin and clavulanic acid, alone and in combination, reduced the incidence of inclusion formation of all three strains. Particularly good activity was observed against the laboratory-adapted strain C. trachomatis Sa2f and a clinical isolate C. trachomatis LB1, where a progressive reduction in numbers of inclusions was observed with time. Minocycline and oxytetracycline were the most active agents tested. In an experimental animal model, mice were inoculated intranasally with C. trachomatis MoPn (ATCC VR123) which caused a fatal pneumonia within 16 days, and treated orally for four days commencing at 24 h after infection. At doses producing clinically achievable serum concentrations, amoxycillin (10 mg/kg), amoxycillin/clavulanic acid (10 + 5 mg/kg) and minocycline (5 mg/kg) all protected the mice over a 21-day period. The majority of the animals treated with clavulanic acid alone (20 mg/kg) survived the infection. Treatment with oxytetracycline was less effective, a dose of 160 mg/kg being required to protect 70% of the mice. The results indicate that amoxycillin and amoxycillin/clavulanic acid were more effective against C. trachomatis MoPn in vivo than might be predicted from in-vitro data, suggesting that amoxycillin/clavulanic acid may have potential for the treatment of polymicrobial infections involving C. trachomatis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1885420     DOI: 10.1093/jac/27.5.627

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice.

Authors:  X X Bin; K Wolf; T Schaffner; R Malinverni
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii.

Authors:  Alejandro Beceiro; Rafael López-Rojas; Juan Domínguez-Herrera; Fernando Docobo-Pérez; Germán Bou; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

3.  Characteristics of murine model of genital infection with Chlamydia trachomatis and effects of therapy with tetracyclines, amoxicillin-clavulanic acid, or azithromycin.

Authors:  A S Beale; P A Upshon
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

4.  Commonly prescribed β-lactam antibiotics induce C. trachomatis persistence/stress in culture at physiologically relevant concentrations.

Authors:  Jennifer Kintner; Dawn Lajoie; Jennifer Hall; Judy Whittimore; Robert V Schoborg
Journal:  Front Cell Infect Microbiol       Date:  2014-04-11       Impact factor: 5.293

5.  Vaginal chlamydial clearance following primary or secondary infection in mice occurs independently of TNF-α.

Authors:  Sangamithra Kamalakaran; Bharat K R Chaganty; Rishein Gupta; M Neal Guentzel; James P Chambers; Ashlesh K Murthy; Bernard P Arulanandam
Journal:  Front Cell Infect Microbiol       Date:  2013-03-11       Impact factor: 5.293

6.  Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host.

Authors:  Aonghus Lavelle; Thomas Walter Hoffmann; Hang-Phuong Pham; Philippe Langella; Eric Guédon; Harry Sokol
Journal:  Microbiome       Date:  2019-08-02       Impact factor: 14.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.